Avis et décisions de la HAS
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
Voir aussi
Avis et décisions de la HAS
17/11/2017
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
B7npATmbuFDHmmht
Écouter
